PSEN1 and Alzheimer disease: Given the anti-inflammatory effects of fingolimod and the potentially beneficial effects of this FDA-approved drug on BDNF/TrkB signaling, we set out to explore the capacity of fingolimod to be repurposed for the treatment of AD-like pathology in an amyloid precursor protein/presenilin-1 APP/PS1 Alzheimer mouse model.